tirzepatide surpass trials SURPASS-2 (NEJM 2021) was the definitive head-to-head: vs semaglutide 1.0 mg (the maximum approved T2DM dose) in 1,879 patients with type 2 diabetes. All three tirzepatide doses produced superior HbA1c reductions New research from the SURPASS-EARLY

Individual needs vary based on activity level, climate, and other factors

Increased Oxidative Stress: When you stop taking glutathione, your bodys ability to combat oxidative stress may be reduced

Serious cardiac, hepatic, or renal disease (risk of edema with testosterone therapy)

A potential downside to step therapy is that by requiring you to try less expensive drugs, it may disrupt your care, especially if your healthcare provider recommends a medication like Zepbound that isnt the insurers preferred treatment

Heres who may benefit the most: 1

Why is it important to monitor patient responses closely to pain medication